Perspective Therapeutics, Inc. (NYSE:CATX) Shares Acquired by Deerfield Management Company L.P. Series C

Deerfield Management Company L.P. Series C grew its position in shares of Perspective Therapeutics, Inc. (NYSE:CATX) by 4.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,938,754 shares of the company’s stock after purchasing an additional 120,991 shares during the period. Deerfield Management Company L.P. Series C’s holdings in Perspective Therapeutics were worth $9,375,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Y Intercept Hong Kong Ltd purchased a new position in Perspective Therapeutics during the fourth quarter worth about $33,000. Aigen Investment Management LP purchased a new stake in Perspective Therapeutics during the fourth quarter worth approximately $34,000. National Bank of Canada FI raised its stake in shares of Perspective Therapeutics by 549,900.0% in the 4th quarter. National Bank of Canada FI now owns 11,000 shares of the company’s stock valued at $35,000 after acquiring an additional 10,998 shares during the period. Vontobel Holding Ltd. acquired a new position in shares of Perspective Therapeutics during the fourth quarter worth about $51,000. Finally, Mercer Global Advisors Inc. ADV acquired a new position in Perspective Therapeutics during the 4th quarter worth approximately $51,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics Trading Up 4.9 %

Shares of CATX stock opened at $2.35 on Thursday. Perspective Therapeutics, Inc. has a 1-year low of $1.60 and a 1-year high of $19.05. The stock’s fifty day simple moving average is $2.26 and its 200-day simple moving average is $4.16.

Analyst Upgrades and Downgrades

A number of research firms recently commented on CATX. Scotiabank assumed coverage on Perspective Therapeutics in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 price target for the company. Brookline Capital Management upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a research report on Monday, March 10th. Lifesci Capital raised shares of Perspective Therapeutics to a “strong-buy” rating in a report on Thursday, March 6th. Cantor Fitzgerald upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a report on Tuesday, March 4th. Finally, Truist Financial dropped their target price on Perspective Therapeutics from $21.00 to $10.00 and set a “buy” rating on the stock in a report on Monday, April 7th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, Perspective Therapeutics has a consensus rating of “Buy” and an average price target of $12.75.

Insider Transactions at Perspective Therapeutics

In other news, CFO Juan Graham purchased 33,333 shares of the business’s stock in a transaction dated Friday, March 28th. The stock was bought at an average cost of $2.25 per share, with a total value of $74,999.25. Following the purchase, the chief financial officer now directly owns 35,354 shares of the company’s stock, valued at approximately $79,546.50. This trade represents a 1,649.33 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Robert F. Williamson III purchased 22,192 shares of the stock in a transaction that occurred on Friday, March 28th. The stock was purchased at an average cost of $2.27 per share, with a total value of $50,375.84. Following the purchase, the director now owns 70,837 shares in the company, valued at $160,799.99. This represents a 45.62 % increase in their position. The disclosure for this purchase can be found here. Insiders purchased 115,696 shares of company stock valued at $256,344 over the last three months. 3.72% of the stock is owned by corporate insiders.

Perspective Therapeutics Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.